Genus (LON:GNS) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Genus plc (LON:GNSGet Free Report)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,810.28 ($23.51) and traded as high as GBX 1,994 ($25.90). Genus shares last traded at GBX 1,992 ($25.87), with a volume of 87,838 shares traded.

Analyst Ratings Changes

Separately, Shore Capital reissued a “buy” rating on shares of Genus in a research report on Wednesday, December 11th.

View Our Latest Stock Report on Genus

Genus Stock Performance

The firm has a 50 day moving average of GBX 1,788.57 and a two-hundred day moving average of GBX 1,810.28. The stock has a market cap of £1.30 billion, a PE ratio of 165.12, a PEG ratio of 2.87 and a beta of 0.37. The company has a debt-to-equity ratio of 53.12, a current ratio of 1.80 and a quick ratio of 1.08.

Genus (LON:GNSGet Free Report) last posted its earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) earnings per share for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. Research analysts predict that Genus plc will post 70.9644323 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jorgen Kokke sold 19,967 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($22.48), for a total transaction of £345,628.77 ($448,926.83). 0.75% of the stock is owned by company insiders.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Further Reading

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.